iPAVE – imaging Pituitary ActiVation by Exendin - GLP1-hypophysis

Radboud university medical center0 个研究点目标入组 20 人开始时间: 2018年10月17日最近更新: 2019年2月28日

试验速览

暂无简介。

•Inclusion criteria (patients with treatment response)
•-Age =18 years
•-Subject is diagnosed with type 2 diabetes
•-Subject showed response to GLP-1RA treatment (decrease in HbA1c =5 mmol/mol and/or weight loss =5%)
•-Ability to sign informed consent
•Inclusion criteria (patients without treatment response)
•-Age =18 years
•-Subject is diagnosed with type 2 diabetes
•-Subject showed no response to GLP-1RA treatment (decrease in HbA1c <5 mmol/mol and no weight loss)
•-Ability to sign informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of the normal range
•- Renal disease defined as MDRD <40 ml/min/1.73 m^2
•- Pregnancy or the wish to become pregnant within 6 months after the study
•- Breastfeeding
•- Age <18 years
•- Pituitary disorder
•- lnability to sign informed consent

发起方